Eisele Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 17, 2024
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-01-16$66.30/sh+28,367$1,880,732→ 28,367 totalExercise: $66.30Exp: 2034-01-15→ Common Stock (28,367 underlying) - Award
Common Stock
2024-01-16+19,508→ 73,088 total - Sale
Common Stock
2024-01-16$66.81/sh−438$29,262→ 72,650 total
Footnotes (3)
- [F1]This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service.
- [F2]This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/12/2024.
- [F3]This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.